|
1
|
Assi HA, Khoury KE, Dbouk H, Khalil LE,
Mouhieddine TH and El Saghir NS: Epidemiology and prognosis of
breast cancer in young women. J Thorac Dis. 5:S2–S8.
2013.PubMed/NCBI
|
|
2
|
De Santis C, Siegel R, Bandi P and Jemal
A: Breast cancer statistics. CA Cancer J Clin. 61:409–418.
2011.
|
|
3
|
Provenzano E, Brown JP and Pinder SE:
Pathological controversies in breast cancer: classification of
ductal carcinoma in situ, sentinel lymph nodes and low volume
metastatic disease and reporting of neoadjuvant chemotherapy
specimens. Clin Oncol (R Coll Radiol). 25:80–92. 2013.
|
|
4
|
Boyle DP, McCourt CM, Matchett KB and
Salto-Tellez M: Molecular and clinicopathological markers of
prognosis in breast cancer. Expert Rev Mol Diagn. 13:481–498. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ailles LE and Weissman IL: Cancer stem
cells in solid tumors. Curr Opin Biotechnol. 18:460–466. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tirino V, Desiderio V, Paino F, et al:
Cancer stem cells in solid tumors: an overview and new approaches
for their isolation and characterization. FASEB J. 27:13–24. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
10
|
Fang D, Nguyen TK, Leishear K, et al: A
tumorigenic subpopulation with stem cell properties in melanomas.
Cancer Res. 65:9328–9337. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tirino V, Desiderio V, Paino F, et al:
Human primary bone sarcomas contain CD133+ cancer stem
cells displaying high tumorigenicity in vivo. FASEB J.
25:2022–2030. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu A, Feng B, Gu W, Cheng X, Tong T,
Zhang H and Hu Y: The CD133+ subpopulation of the SW982
human synovial sarcoma cell line exhibits cancer stem-like
characteristics. Int J Oncol. 42:1399–1407. 2013.
|
|
13
|
Liu J, Ma L, Xu J, Liu C, Zhang J, Liu J,
Chen R and Zhou Y: Spheroid body-forming cells in the human gastic
cancer cell line MKN-45 possess cancer stem cell properties. Int J
Oncol. 42:453–459. 2013.PubMed/NCBI
|
|
14
|
Al-Hajj M and Clarke MF: Self-renewal and
solid tumor stem cells. Oncogene. 23:7274–7282. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dean M, Fojo T and Bates S: Tumor stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar
|
|
16
|
Bao B, Ahmad A, Azmi AS, Ali S and Sarkar
FH: Overview of cancer stem cells (CSCs) and mechanisms of their
regulation: implications for cancer therapy. Curr Protoc Pharmacol.
Chapter 14(Unit 14): 252013.PubMed/NCBI
|
|
17
|
Chuthapisith S, Eremin J, El-Sheemey M and
Eremin O: Breast cancer chemoresistance: emerging importance of
cancer stem cells. Surg Oncol. 19:27–32. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yan W, Chen Y, Yao Y, Zhang H and Wang T:
Increased invasion and tumorigenicity capacity of
CD44+/CD24− breast cancer MCF7 cells in
vitro and in nude mice. Cancer Cell Int. 13:622013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
De Beca FF, Caetano P, Gerhard R,
Alvarenga CA, Gomes M, Paredes J and Schmitt F: Cancer stem cells
markers CD44, CD24 and ALDH1 in breast cancer special histological
types. J Clin Pathol. 66:187–191. 2013.PubMed/NCBI
|
|
20
|
Leth-Larsen R, Terp MG, Christensen AG, et
al: Functional heterogeneity within the CD44 high human breast
cancer stem cell-like compartment reveals a gene signature
predictive of distant metastasis. Mol Med. 18:1109–1121. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wei W, Hu H, Tan H, Chow LW, Yip AY and
Loo WT: Relationship of CD44+CD24−/low breast
cancer stem cells and axillary lymph node metastasis. J Transl Med.
10:S1–S6. 2012.
|
|
22
|
Lin Y, Zhong Y, Guan H, Zhang X and Sun Q:
CD44+/CD24− phenotype contributes to
malignant relapse following surgical resection and chemotherapy in
patients with invasive ductal carcinoma. J Exp Clin Cancer Res.
4:31–59. 2012.
|
|
23
|
Sheridan C, Kishimoto H, Fuchs RK, et al:
CD44+/CD24− breast cancer cells exhibit
enhanced invasive properties: an early step necessary for
metastasis. Breast Cancer Res. 8:R592006. View Article : Google Scholar
|
|
24
|
Abraham BK, Fritz P, McClellan M,
Hauptvogel P, Athelogou M and Brauch H: Prevalence of
CD44+/CD24−/low cells in breast cancer may
not be associated with clinical outcome but may favor distant
metastasis. Clin Cancer Res. 11:1154–1159. 2005.PubMed/NCBI
|
|
25
|
Viale G: The current state of breast
cancer classification. Ann Oncol. 23:207–210. 2012. View Article : Google Scholar
|
|
26
|
Cassol L, Silveira Graudenz M, Zelmanowicz
A, Candela A, Werutsky G, Rovere RK and Garicochea B: Basal-like
immunophenotype markers and prognosis in early breast cancer.
Tumori. 96:966–970. 2010.PubMed/NCBI
|
|
27
|
Lavasani MA and Moinfar F: Molecular
classification of breast carcinomas with particular emphasis on
‘basal-like’ carcinoma: acritical review. J Biophotonics.
5:345–366. 2012.
|
|
28
|
Toft DJ and Cryns VL: Minireview:
basal-like breast cancer: from molecular profiles to targeted
therapies. Mol Endocrinol. 25:199–211. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ponti D, Costa A, Zaffaroni N, et al:
Isolation and in vitro propagation of tumorigenic breast cancer
cells with stem/progenitor cell properties. Cancer Res.
65:5506–5511. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lehmann C, Jobs G, Thomas M, Burtscher H
and Kubbies M: Established breast cancer stem cell markers do not
correlate with in vivo tumorigenicity of tumor-initiating cells.
Int J Oncol. 41:1932–1942. 2012.PubMed/NCBI
|
|
31
|
Jaggupilli A and Elkord E: Significance of
CD44 and CD24 as cancer stem cell markers: an enduring ambiguity.
Clin Dev Immunol. 2012:7080362012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Seton-Rogers S: Metastasis: signalling in
transit. Nat Rev Cancer. 12:42011.
|
|
33
|
Nguyen DX, Bos PD and Massagué J:
Metastasis: from dissemination to organ-specific colonization. Nat
Rev Cancer. 9:274–284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Baumann P, Cremers N, Kroese F, et al:
CD24 expression causes the acquisition of multiple cellular
properties associated with tumor growth and metastasis. Cancer Res.
65:10783–10793. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dontu G, El-Ashry D and Wicha MS: Breast
cancer, stem/progenitor cells and the estrogen receptor.
Trends Endocrinol Metab. 15:193–197. 2004. View Article : Google Scholar
|
